Venture Capital

As co-founder Jürgen Bickel steps down, 14-year veteran David Männer takes the helm to navigate Storz & Bickel's future and drive Canopy's U.S. plans.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Kontrol Technologies targets Ontario's aging apartments with a strategic HVAC buyout, but its cautious M&A history reveals a complex path forward.

The company aims to slash production costs by 50% with AI, while deploying a powerful open-source agent that brings both promise and significant risk.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

OPAL Fuels' Co-CEO will keynote at ACT Expo, highlighting how renewable natural gas offers fleets a path to cost savings and deep decarbonization.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

With $12M in new funding, a Houston startup is deploying its NASA-derived HVAC retrofit that promises to slash building energy bills by over 50%.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.

An Austin-based firm's rapid expansion to 150 partners shows how CE/CME is moving from conference halls to podcasts, apps, and on-demand platforms.

A new report reveals a stark divide in U.S. child care funding. A family's access to care—and their economic future—increasingly depends on their state.

The World Series of Poker is back on ESPN with a new format and producer Peyton Manning. Can this high-stakes partnership recapture the magic of the 2000s?

Cult popcorn brand Opopop is betting its bold flavors can disrupt the snack aisle with a nationwide Walmart launch. Can this online darling win over the masses?

As OpenAI shelves its costly Sora video project, smaller firms like ReelTime tout a new path: efficiency over brute force. Is this the future of AI video?

A new wave of drug-free hair restoration combines ancient botanicals with FDA-cleared light therapy, challenging the chemical-reliant status quo.

A US firm is bringing embryo screening for chronic diseases to major IVF networks, sparking debate on the future of family planning and genetic health.

Renowned cardiac surgeon Dr. Robert C. Robbins brings his immense credibility to Linear Health Sciences, aiming to revolutionize patient care with a novel device.